Loading asset research
OnKure Therapeutics Inc. Class A Common Stock
OKURNasdaq · USD · StocksQuote as of · Exchange session not verified$3.10
-5.20%
Today
OKUR
Loading 1D prices…
Market cap
$125.5M
Volume
253.6K
52w high
$5.3852w low
$2.23Company profile
OnKure Therapeutics Inc. Class A Common Stock
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boulder, CO, United States
Employees
45
Fiscal year end
1231
CIK
1637715
Session & valuation
Open$3.31
Previous close$3.27
Day high$3.33
Day low$2.98
30-day avg. volume158.8K
Outstanding shares40.5M
Diluted EPS-$4.40
Latest annual period
P/E (trailing)-0.70
P/E (forward)-2.03
Price / book0.73
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BMEABiomea Fusion Inc. Common Stock | $125.8M | $0.00 | — | -$1.18 | +2.35% | Buy |
| VTVTvTv Therapeutics Inc. Class A Common Stock | $126.4M | $0.00 | — | -$3.20 | +0.35% | Buy |
| KZIAKazia Therapeutics Limited American Depositary Shares | $127.9M | — | — | -$18.90 | +1.63% | Buy |
| CNTBConnect Biopharma Holdings Limited Ordinary Shares | $128.5M | $64K | -86687.50% | -$1.00 | -0.97% | Buy |
| TLSATiziana Life Sciences Ltd. Common Shares | $122.2M | $0.00 | — | -$0.16 | 0.00% | Buy |